Gastric Cancer Market Set to Reach $16.5 Billion by 2035

Gastric cancer market was valued at $7.5 billion in 2025 and is projected to reach $16.5 billion by 2035, growing at a CAGR of 8.3% during the forecast period (2026-2035). Gastric cancer remains a significant global health burden, with approximately 968,000–1.09 million new cases diagnosed annually and over 660,000–769,000 deaths worldwide, making it the fifth most common cancer and a leading cause of cancer mortality. Despite declining incidence rates in some regions, the absolute number of cases continues to rise due to population growth and aging, with projections indicating further increases in disease burden over the coming decades. Among this evolving landscape, the gastric cancer treatment market is undergoing a paradigm shift driven by advancements in immunotherapy. Historically limited to late-line settings, immunotherapy has rapidly transitioned into first-line and perioperative treatment regimens, significantly altering clinical practice. The integration of chemotherapy combined with immune checkpoint inhibitors has become a widely adopted standard approach across advanced and metastatic gastric cancer cases. Clinical studies have demonstrated that such combination therapies can deliver complete response rates of up to 20% in select patient populations, highlighting substantial improvements in treatment efficacy. This shift is expanding the eligible patient pool and increasing treatment duration, thereby enhancing overall market value. Furthermore, immunotherapy is enabling more personalized treatment strategies, particularly when guided by biomarkers such as PD-L1 expression. As a result, pharmaceutical companies are increasingly focusing on combination regimens and expanding indications to capture larger patient segments. Overall, the transition of immunotherapy into earlier lines of treatment is emerging as a key growth driver in the global gastric cancer market, reshaping both clinical outcomes and commercial dynamics.

Browse the full report description of “Gastric Cancer Market Size, Share & Trends Analysis Report by Testing Type (Chest X-Ray, Computed Tomography (CT OR CAT) Scan, Laparoscopy, MRI Scan, PET Scan and Others), by Treatment Type (Chemotherapy, Radiation Therapy, Surgery, Targeted Therapy and Immunotherapy), and by End-User (Hospitals & Clinics, Specialized Cancer Treatment Centers and Others), Forecast Period (2026-2035)” at https://www.omrglobal.com/industry-reports/gastric-cancer-market

Key Industry Developments and Strategic Advancements in the Gastric Cancer Market

The major companies operating in the global Gastric Cancer market include AstraZeneca plc, Bristol-Myers Squibb Company, Eli Lilly and Company, F. Hoffmann-La Roche Ltd. and Merck & Co., Inc., among others.

• In November 2025, Jazz Pharmaceuticals and Zymeworks reported positive trial results for zanidatamab in gastroesophageal adenocarcinoma, demonstrating statistically significant improvements in progression-free survival compared with trastuzumab plus chemotherapy. The combination of zanidatamab with chemotherapy and Tevimbra also showed a significant overall survival benefit, while the dual-chemotherapy regimen indicated a positive trend. The companies plan to seek approval from the U.S. Food and Drug Administration in 2026, positioning the therapy as a potential alternative in HER2-positive gastric cancer treatment.

• In October 2024, the U.S. Food and Drug Administration approved zolbetuximab-clzb with chemotherapy for first-line treatment of CLDN18.2-positive, HER2-negative gastric or gastroesophageal junction adenocarcinoma, alongside approval of the VENTANA CLDN18 (43-14A) RxDx Assay to identify eligible patients. The decision was supported by the SPOTLIGHT trial and GLOW trial, which showed improved progression-free and overall survival compared with chemotherapy alone.

Market Coverage

• The market number available for – 2025-2035
• Base year- 2025
• Forecast period- 2026-2035
• Segment Covered-  
• Testing Type
• Treatment Type
• End-User
• Competitive Landscape – AstraZeneca Plc, Bristol-Myers Squibb Company, Eli Lilly and Company, F. Hoffmann-La Roche Ltd. and Merck & Co., Inc.

Key questions addressed by the report.

• What is the market growth rate?
• Which segment and region dominate the market in the base year?
• Which segment and region will project the fastest growth in the market?
• Who is the leader in the market?
• How are players addressing challenges to sustain growth?
• Where is the investment opportunity?

Global Gastric Cancer Market Report Segment

By Testing Type

• Chest X-Ray
• Computed Tomography (CT OR CAT) Scan
• Laparoscopy
• MRI Scan
• PET Scan
• Others

By Treatment Type

• Chemotherapy
• Radiation Therapy
• Surgery
• Targeted Therapy
• Immunotherapy

By End-User

• Hospitals & Clinics
• Specialized Cancer Treatment Centers
• Others

Global Gastric Cancer Market Report Segment by Region

North America

• United States
• Canada

Europe

• UK
• Germany
• Italy
• Spain
• France
• Russia
• Rest of Europe

Asia-Pacific

• China
• India
• Japan
• South Korea
• Australia and New Zealand
• ASEAN Economies
• Rest of Asia-Pacific

Rest of the World

• Latin America
• Middle East & Africa

To learn more about this report request a sample copy @ https://www.omrglobal.com/request-sample/gastric-cancer-market